Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861457 | 0.87 | CYP1A2 (1.00) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL6121350 | 0.85 | CYP1A2 (0.95) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL6847321 | 0.85 | CYP1A2 (0.71) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL19031318 | 0.83 | CYP1A2 (0.83) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL10054984 | 0.83 | CYP1A2 (0.91) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL29875178 | 0.83 | CYP1A2 (0.83) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL22304865 | 0.82 | CYP1A2 (0.88) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL1042402 | 0.82 | CYP1A2 (0.88) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL1037867 | 0.80 | CYP1A2 (0.77) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 | |
| SCHEMBL12651972 | 0.80 | CYP1A2 (0.77) | CYP1A2CYP2D6CHRM2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1310934-C | Erythromycin 6-O-carbamoylketolide derivatives useful as antibacterial agents | ORTHO MCNEIL PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1543472-A | 6-o-carbamoyl ketolide antibacterials | ����-������ҩƷ��˾ | 2004-11-03 | — | — | CN | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| US-6087357-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| US-5847150-A | Solid phase and combinatorial synthesis of substituted 2-methylene-2, 3-dihydrothiazoles and of arrays of substituted 2-methylene-2, 3-dihydrothiazoles | NOVO NORDISK A/S (DK) | 1998-12-08 | — | — | US | disclosed |
| US-5747485-A | RESPIRATORY SYSTEM DISORDERS | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010182-A1 | Piperazine derivatives as tachykinin antagonists | PKD2, SSTR5, TAC3 | CYP1A2 2723/4885CYP2D6 2982/4885CHRM2 1130/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | CYP1A2 3028/4885CYP2D6 234/4885CHRM2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.